US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Genomics Immunology and Healthcare ETF

38.43

-0.3100-0.80%

Volume:58.61K

Turnover:2.25M

Market Cap:259.40M

PE:- -

High:38.61

Open:38.55

Low:38.17

Close:38.74

52wk High:41.49

52wk Low:22.33

Shares:6.75M

Float Shares:6.75M

Volume Ratio:0.71

T/O Rate:0.87%

Dividend:0.28

Dividend Rate:0.74%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Transgene Jumps 20% on Positive Cancer Vaccine Data in Early Trial

Poolbeg Pharma to spotlight POLB 001 at global scientific and investor conferences

Buy Rating Reiterated on Daraxonrasib Strength, RASolve 301 Upsizing, and Unchanged $315 Price Target

Vertex Minerals Seeks Trading Halt Ahead of Capital Raising Plan

NEJM publishes Phase 1/2 clinical data on daraxonrasib

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

Inventiva announces last patient visit in NATiV3 trial

Revolution Medicines Director Lorence H. Kim Disposes of Common Shares Worth $11.21 Million

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Alumis Inc. (ALMS) and Medtronic (MDT)

Evotec, Plectonic Biotech announce immunotherapy research collaboration

Wall Street Analysts Are Bullish on Top Healthcare Picks

What Does Crinetics Pharmaceuticals (CRNX) Delisting Mean After The Takeover Closed?

Simply Wall St.

FedEx Incheon Gateway Wins IATA CEIV Pharma Certification

Moderna Plans Private Placement of $2 Billion Convertible Senior Notes Due 2032

Moderna Inc. Stock Advances 9.9%, Outperforms Peers

S&P 500 Top and Bottom Performing Stocks at About 12:00 P.m. EDT

Vertex Pharmaceuticals Closes Crinetics Pharmaceuticals Acquisition

MT Newswires Live

Vertex Pharmaceuticals completes acquisition of Crinetics Pharmaceuticals

Vertex Names Jonathan Poole CFO Effective Jan. 1, 2027

Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/IDNA/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IDNA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","market":"US","secType":"STK","nameCN":"iShares Genomics Immunology and Healthcare ETF","latestPrice":38.43,"timestamp":1789489412567,"preClose":38.74,"halted":0,"volume":58607,"delay":0,"changeRate":-0.008002065049044974,"floatShares":6750000,"shares":6750000,"eps":0,"marketStatus":"Trading","change":-0.31,"latestTime":"09-15 12:24:41 EDT","open":38.549,"high":38.61,"low":38.165,"amount":2246306.502279,"amplitude":0.011487,"askPrice":38.49,"askSize":400,"bidPrice":38.32,"bidSize":300,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789502400000},"marketStatusCode":2,"adr":0,"exchange":"ARCA","adjPreClose":38.74,"sharesOutstanding":5100000,"nav":37.991633,"aum":258343104.4,"dividendRate":0.007359,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":38.74,"preClose":38.74,"latestTime":"19:30 EDT","volume":75,"amount":2918.7,"timestamp":1789428601745,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.707344,"impliedVol":0.1957,"impliedVolPercentile":0.498},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","floatShares":6750000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.707344,"shares":6750000,"dividePrice":0.2828,"high":38.61,"amplitude":0.011487,"preClose":38.74,"low":38.165,"week52Low":22.33,"pbRate":"--","week52High":41.49,"institutionHeld":0,"latestPrice":38.43,"committee":-0.142857,"eps":0,"divideRate":0.007359,"volume":58607,"delay":0,"ttmEps":0,"open":38.549,"prevYearClose":26.19,"prevWeekClose":38.06,"prevMonthClose":39.26,"prevQuarterClose":33.75,"fiveDayClose":39.23,"twentyDayClose":35.86,"sixtyDayClose":30.56},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IDNA\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"IDNA","amount":0.125421,"announcedDate":"2026-06-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2025-12-16","symbol":"IDNA","amount":0.155456,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2025-06-16","symbol":"IDNA","amount":0.152909,"announcedDate":"2025-06-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-16","defaultRemindTime":1750080600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-20","payableDate":"2025-06-16","currency":"USD","dateTimestamp":1750046400000,"payDate":"2025-06-20"},{"date":"2024-12-17","symbol":"IDNA","amount":0.11105,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2024-06-11","symbol":"IDNA","amount":0.11144,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-11","defaultRemindTime":1718112600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-17","payableDate":"2024-06-11","currency":"USD","dateTimestamp":1718078400000,"payDate":"2024-06-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IDNA\",market:\"US\",,,undefined,":[{"executeDate":"2019-12-16","recordDate":"2019-12-17","paymentDate":"2019-12-20","value":0.237063,"currency":"USD"},{"executeDate":"2020-06-15","recordDate":"2020-06-16","paymentDate":"2020-06-19","value":0.083667,"currency":"USD"},{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-18","value":0.036209,"currency":"USD"},{"executeDate":"2021-06-10","recordDate":"2021-06-11","paymentDate":"2021-06-16","value":0.052145,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-17","value":0.256358,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IDNA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IDNA\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664982743","title":"Transgene Jumps 20% on Positive Cancer Vaccine Data in Early Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2664982743","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664982743?lang=en_us&edition=fundamental","pubTime":"2026-09-03 16:20","pubTimestamp":1788423613,"startTime":"0","endTime":"0","summary":"Transgene jumps 20% on positive cancer vaccine data in early trialSept 3 (Reuters)-TransgeneTRNG.PAshares surged 20% in early Paris trading on Thursday, after the French biotechnology company reported","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nL6N44V0L4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNOM","IDNA","BK4585","BK4548","BK4568","BK4139","BK4534","BK4533","LGHT","MRNX","BK4532","BK4588","WDNA","MRNA","MRNY","BK4551","BK4501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664682193","title":"Poolbeg Pharma to spotlight POLB 001 at global scientific and investor conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2664682193","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664682193?lang=en_us&edition=fundamental","pubTime":"2026-09-03 14:09","pubTimestamp":1788415748,"startTime":"0","endTime":"0","summary":"Poolbeg Pharma Ltd. ( ($GB:POLB) ) has issued an update. Poolbeg Pharma will showcase its lead cancer immunotherapy-support asset POLB 001 and broa...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/poolbeg-pharma-to-spotlight-polb-001-at-global-scientific-and-investor-conferences?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/poolbeg-pharma-to-spotlight-polb-001-at-global-scientific-and-investor-conferences?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664828323","title":"Buy Rating Reiterated on Daraxonrasib Strength, RASolve 301 Upsizing, and Unchanged $315 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2664828323","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664828323?lang=en_us&edition=fundamental","pubTime":"2026-09-03 09:25","pubTimestamp":1788398717,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Charles Zhu maintained a Buy rating on Revolution Medicines yesterday and set a price target of $315.00. Charles Zhu has gi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-reiterated-on-daraxonrasib-strength-rasolve-301-upsizing-and-unchanged-315-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-reiterated-on-daraxonrasib-strength-rasolve-301-upsizing-and-unchanged-315-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PTH","IE00B2B36J28.USD","BK4139","LU0889565916.HKD","IDNA","CANC","IE0002141913.USD","IE0009355771.USD","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","LU0320765992.SGD","IE00BJT1NW94.SGD","IE0009354923.USD","BBH","LU0109394709.USD","RVMD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664422868","title":"Vertex Minerals Seeks Trading Halt Ahead of Capital Raising Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2664422868","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664422868?lang=en_us&edition=fundamental","pubTime":"2026-09-03 07:44","pubTimestamp":1788392661,"startTime":"0","endTime":"0","summary":"Vertex Minerals Ltd. ( ($AU:VTX) ) has shared an update. Vertex Minerals Ltd, an Australian minerals and resources company listed on the ASX as VTX...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vertex-minerals-seeks-trading-halt-ahead-of-capital-raising-plan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vertex-minerals-seeks-trading-halt-ahead-of-capital-raising-plan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0289739699.SGD","BK4532","IE00B2B36J28.USD","GNMX","LU2362541513.USD","LU2362541273.HKD","LU0061475181.USD","PBE","LU0823416689.USD","IBB","IBBQ","IE0009355771.USD","LU0757428866.USD","LU2324357040.USD","TBXU","LU1559883803.SGD","SG9999001176.SGD","LU2237438978.USD","LU0079474960.USD","LU0889565916.HKD","MTX","IE00BFTCPJ56.SGD","LU1585245621.USD","LU1674673691.USD","SG9999013999.USD","VERX","IE00BZ9MQY76.HKD","LU0256863811.USD","IE00B19Z9P08.USD","LU2417539215.USD","LU2362540622.SGD","LU1430594728.SGD","BIB","IE00B19Z9Z06.USD","LU2236285917.USD","LU0058720904.USD","IDNA","BBH","LU0320765992.SGD","IE00B19Z3B42.SGD","LU0432979614.USD","LU2456880835.USD","IE0002141913.USD","VRTX","LU0109394709.USD","BK4023","IE00B4R5TH58.HKD","SGXZ57979304.SGD","BK4585","SG9999001176.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664844659","title":"NEJM publishes Phase 1/2 clinical data on daraxonrasib","url":"https://stock-news.laohu8.com/highlight/detail?id=2664844659","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664844659?lang=en_us&edition=fundamental","pubTime":"2026-09-03 05:55","pubTimestamp":1788386116,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) “announced that The New England Journal of Medicine has published a report describing data from the Phase 1/2 clinical ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nejm-publishes-phase-1-2-clinical-data-on-daraxonrasib-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nejm-publishes-phase-1-2-clinical-data-on-daraxonrasib-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0009354923.USD","CANC","IE0002141913.USD","IDNA","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU0109394709.USD","PTH","RVMD","LU0889565916.HKD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","BK4139","BBH","IE0009355771.USD","LU0320765992.SGD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664844613","title":"New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2664844613","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664844613?lang=en_us&edition=fundamental","pubTime":"2026-09-03 05:50","pubTimestamp":1788385800,"startTime":"0","endTime":"0","summary":"Results support the clinical rationale for RASolve 301, an ongoing Phase 3 trial in RAS mutant metastatic non-small cell lung cancer REDWOOD CITY, Calif., Sept.  02, 2026 (GLOBE NEWSWIRE) --  Revoluti","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/02/3355564/0/en/new-england-journal-of-medicine-publishes-phase-1-2-clinical-data-on-revolution-medicines-rasonque-daraxonrasib-in-metastatic-non-small-cell-lung-cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU1854104046.USD","PTH","LU2487616109.SGD","LU1978683503.SGD","LU2357305700.SGD","IE00BJT1NW94.SGD","IE0002141913.USD","LU1854103824.USD","LU0348723411.USD","BBH","BK4588","IE00B2B36J28.USD","LU0889565916.HKD","IE00BJJMRZ35.SGD","IE00BZ199S13.USD","LU2298322129.HKD","IE0009354923.USD","NVIB","IE00BD6J9T35.USD","LU1861215975.USD","GDOC","IDNA","BMED","ON","ONG","LU0724618433.USD","BK4512","BK4605","LU1720051017.SGD","ONX","LU0109394709.USD","IE0009355771.USD","LU0124384867.USD","IE00BFTCPJ56.SGD","L","LU0053666078.USD","LU1861219969.SGD","BK4585","CANC","IE00B4R5TH58.HKD","LU1861220033.SGD","LU1983260115.SGD","IE00BFMHRM44.USD","RVMD","BK4139","BK4141","LU2360107325.USD","LU1548497426.USD","BK4107"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664841533","title":"Inventiva announces last patient visit in NATiV3 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2664841533","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664841533?lang=en_us&edition=fundamental","pubTime":"2026-09-03 04:35","pubTimestamp":1788381316,"startTime":"0","endTime":"0","summary":"Inventiva (IVA) announced the last patient has completed their final 72-week visit in the NATiV3 Phase 3 clinical trial evaluating lanifibranor for...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/inventiva-announces-last-patient-visit-in-nativ3-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/inventiva-announces-last-patient-visit-in-nativ3-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","GDOC","MEDX","BK4139","IVA","HYLG","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664984906","title":"Revolution Medicines Director Lorence H. Kim Disposes of Common Shares Worth $11.21 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2664984906","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664984906?lang=en_us&edition=fundamental","pubTime":"2026-09-03 04:31","pubTimestamp":1788381115,"startTime":"0","endTime":"0","summary":"Revolution Medicines director Lorence H. Kim disposes of common shares worth $11.21 millionRevolution Medicines director Lorence H. Kim sold 56,000 common shares on Aug. 31 at about $200.56–$206.15.Sa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL1bnXL6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Revolution Medicines Director Lorence H. Kim Disposes of Common Shares Worth $11.21 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","IE0009355771.USD","CANC","IE0002141913.USD","BBH","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","RVMD","IE0009354923.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","BK4139","IDNA","IE00B2B36J28.USD","LU0320765992.SGD","PTH","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664081594","title":"Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Alumis Inc. (ALMS) and Medtronic (MDT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664081594","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664081594?lang=en_us&edition=fundamental","pubTime":"2026-09-02 18:50","pubTimestamp":1788346221,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vertex Pharmaceuticals (VRTX), Alumis Inc. (ALMS) an...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vertex-pharmaceuticals-vrtx-alumis-inc-alms-and-medtronic-mdt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vertex-pharmaceuticals-vrtx-alumis-inc-alms-and-medtronic-mdt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0058720904.USD","IE0002141913.USD","LU1116320901.HKD","BK4139","GNMX","LU0265550946.USD","LU0158827948.USD","LU1057294990.SGD","LU1061106388.HKD","LU0265550359.USD","TBXU","IDNA","VERX","IE00B3T34201.USD","LU1093756325.SGD","XLV","BIB","IE00B894F039.SGD","BBH","MDT","SG9999001176.SGD","BK4533","LU1674673691.USD","LU2112291526.USD","XBI","LU0128526141.USD","LU2023251221.USD","LABU","IE00B2B36J28.USD","LU2089283258.USD","LU0314106906.USD","LU0162691827.USD","HCSG","LU1291159041.SGD","VRTX","LU1506573853.SGD","BK4588","IBBQ","IE0009355771.USD","LU2456880835.USD","BK4581","IBB","LU0106261372.USD","LU0234570918.USD","LU1778281490.HKD","IE00B19Z3B42.SGD","PBE","ALMS","LU2417539215.USD","LU0496365809.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664890504","title":"Evotec, Plectonic Biotech announce immunotherapy research collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2664890504","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664890504?lang=en_us&edition=fundamental","pubTime":"2026-09-02 17:10","pubTimestamp":1788340227,"startTime":"0","endTime":"0","summary":"Evotec (EVO) and Plectonic Biotech announced a research collaboration to explore an immunotherapy approach for solid tumors. The collaboration addr...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evotec-plectonic-biotech-announce-immunotherapy-research-collaboration-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evotec-plectonic-biotech-announce-immunotherapy-research-collaboration-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4121","XBI","EVO","BK4585","BK4581","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664589238","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2664589238","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664589238?lang=en_us&edition=fundamental","pubTime":"2026-09-02 15:40","pubTimestamp":1788334818,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vertex Pharmaceuticals (VRTX) and Cabaletta Bio (CAB...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-322?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-322?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0566484027.USD","IE00B4R5TH58.HKD","LU0889565916.HKD","SG9999013999.USD","XLV","LU2324357040.USD","BK4581","IBBQ","LU0823416689.USD","IBB","LU1585245621.USD","LU0289739699.SGD","SG9999001176.USD","TBXU","IE00B19Z3B42.SGD","IE00BZ9MQY76.HKD","LU1674673428.USD","BK4588","XBI","IE00B2B36J28.USD","LU0079474960.USD","LU1674673691.USD","LU0029874061.USD","PBE","BK4533","LABU","IE00BJJMRZ35.SGD","LU0432979614.USD","LU2468319806.SGD","VRTX","LU1035775433.USD","HCSG","IE00B19Z9P08.USD","BIB","LU0757428866.USD","GNMX","LU2362540622.SGD","LU1093756325.SGD","IDNA","LU2417539215.USD","BK4567","BBH","LU0320765992.SGD","LU0234570918.USD","LU0109394709.USD","IE00B19Z3581.USD","BK4137","LU2456880835.USD","VERX","LU0061475181.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664689541","title":"What Does Crinetics Pharmaceuticals (CRNX) Delisting Mean After The Takeover Closed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2664689541","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664689541?lang=en_us&edition=fundamental","pubTime":"2026-09-02 10:23","pubTimestamp":1788315823,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals completed its acquisition of Crinetics Pharmaceuticals (NasdaqGS:CRNX), resulting in Crinetics becoming a wholly owned subsidiary.\nCrinetics has been delisted from the Nasdaq, with leadership changes announced as part of its integration into Vertex's operations.\nThe transaction ends Crinetics' status as an independent public company and shifts its future direction under Vertex's control.\n\nFor readers tracking consolidation in biopharma and looking for more stock ideas...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crnx/crinetics-pharmaceuticals/news/what-does-crinetics-pharmaceuticals-crnx-delisting-mean-afte","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crnx/crinetics-pharmaceuticals/news/what-does-crinetics-pharmaceuticals-crnx-delisting-mean-afte","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BBH","IE00B19Z9Z06.USD","IE00BZ9MQY76.HKD","LU0320765992.SGD","LU2456880835.USD","IE0002141913.USD","LU0109394709.USD","LU1815336091.USD","LU0061475181.USD","PBE","BK4588","SGXZ57979304.SGD","IBB","LU2417539215.USD","LU0058720904.USD","IE00BFTCPJ56.SGD","IE0009355771.USD","LU2462157665.USD","BIB","BK4533","SG9999001176.SGD","BK4585","CRNX","IE00BJT1NW94.SGD","VERX","LU1093756325.SGD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0432979614.USD","IE0002270589.USD","LU2362540622.SGD","LU1674673428.USD","LU0256863811.USD","TBXU","BK4567","IBBQ","IDNA","BK4139","VRTX","LU1093756168.USD","LU1430594728.SGD","BK4007","GNMX","LU0417517546.SGD","BK4023","LU0234570918.USD","LU1585245621.USD","IE00B4R5TH58.HKD","LU2237438978.USD","LU1035775433.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664743862","title":"FedEx Incheon Gateway Wins IATA CEIV Pharma Certification","url":"https://stock-news.laohu8.com/highlight/detail?id=2664743862","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664743862?lang=en_us&edition=fundamental","pubTime":"2026-09-02 08:30","pubTimestamp":1788309037,"startTime":"0","endTime":"0","summary":"FedEx Incheon Gateway wins IATA CEIV Pharma certificationFedEx’s Incheon Gateway at Incheon International Airport secured IATA CEIV Pharma certification for temperature-controlled pharmaceutical air c","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL7spGmF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNMX","PBE","LU0823416689.USD","IBBQ","SHPP","LU0072461881.USD","LU2456880835.USD","SG9999013999.USD","IE0002141913.USD","LU0006061336.USD","LU2089984988.USD","BBH","LU1069344957.HKD","LU1778281490.HKD","LU2362541273.HKD","LU0058720904.USD","IE0002270589.USD","LU0061475181.USD","SG9999001176.SGD","LU0251142724.SGD","LU1267930227.SGD","VRTX","IDNA","IE00BFTCPJ56.SGD","LU1674673691.USD","LU1430594728.SGD","BIB","LU2236285917.USD","IE00B19Z9Z06.USD","TBXU","LU2237438978.USD","LU0432979614.USD","BK4585","IE00B4R5TH58.HKD","SGXZ57979304.SGD","IBB","LU0109394709.USD","FDX","LU1035775433.USD","IE00B19Z3B42.SGD","LU1093756325.SGD","IE00B19Z3581.USD","HULL","LU1585245621.USD","LU1571399168.USD","BK4533","LU0310800965.SGD","BK4139","LU0234570918.USD","LU2417539215.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664486915","title":"Moderna Plans Private Placement of $2 Billion Convertible Senior Notes Due 2032","url":"https://stock-news.laohu8.com/highlight/detail?id=2664486915","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664486915?lang=en_us&edition=fundamental","pubTime":"2026-09-02 04:37","pubTimestamp":1788295066,"startTime":"0","endTime":"0","summary":"Moderna plans private placement of $2 billion convertible senior notes due 2032Moderna launched a private placement of USD 2 billion Convertible Senior Notes due 2032, marketed to qualified institutio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL75wNqt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IDNA","MRNY","WDNA","BK4548","BK4534","BK4568","BK4532","BK4501","BK4588","GNOM","MRNA","BK4533","BK4139","LGHT","BK4551","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664901869","title":"Moderna Inc. Stock Advances 9.9%, Outperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2664901869","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664901869?lang=en_us&edition=fundamental","pubTime":"2026-09-02 04:33","pubTimestamp":1788294780,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Moderna Inc. rallied 9.9% to $154.27 on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite Index falling 1.0% to 26,099.77 and Dow Jones Industrial Average falling 0.8% to 52,766.88.This was the stock's second consecutive day of gains.Moderna Inc. closed 12.7% short of its 52-week high of $176.66, which the company achieved on August 19th.The stock outperformed some of its peers, as Johnson & Johnson rose 2.0% to $271.19, Pfizer Inc. rose 0.3% to $28.55, and Gilead Sciences Inc. rose 2.45% to $149.92.Trading volume totaled 25.3 million, compared to the 50-day average of 16.8 million.Data source: Dow Jones Market Data, FactSet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD","IDNA","LU2112291526.USD","MRNY","BK4588","LU0823416689.USD","BK4583","IBB","LU2468319806.SGD","LU2324357040.USD","BK4566","IE00BZ1G4Q59.USD","BK4501","MEDI","BK4568","LU0109394709.USD","LU0289739699.SGD","GNOM","MRNA","BK4534","LU0965509010.AUD","LU2089984988.USD","BBH","IE00B7SZLL34.SGD","BK4533","IBBQ","LU1057294990.SGD","IE00B19Z3B42.SGD","TBXU","WDNA","LU0234570918.USD","BIB","BMED","BK4139","LU0320765992.SGD","BK4551","LU1934455863.HKD","MRNX","SG9999015945.SGD","LU1934455277.USD","LU1571399168.USD","LU1066053197.SGD","LU1934455194.USD","TMED","LGHT","LU0861579265.USD","LU1430594728.SGD","LU0058720904.USD","LU1037948541.HKD","LU0965508806.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664500918","title":"S&P 500 Top and Bottom Performing Stocks at About 12:00 P.m. EDT","url":"https://stock-news.laohu8.com/highlight/detail?id=2664500918","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664500918?lang=en_us&edition=fundamental","pubTime":"2026-09-02 00:00","pubTimestamp":1788278413,"startTime":"0","endTime":"0","summary":"BUZZ - S&P 500 top and bottom performing stocks at about 12:00 p.m. EDTS&P 500.SPXTop PerformersPercent ChangeModerna, Inc.MRNA.OQ+6.2%Mosaic CoMOS.N+4.2%Dollar Tree IncDLTR.OQ+3.8%Corteva, Inc.CTVA.N+3.6%Dollar General CorpDG.N+3.4%Bottom PerformersPercent ChangeAxon Enterprise, Inc.AXON.OQ-9.1%CrowdStrike Holdings, Inc.CRWD.OQ-6.9%Cadence Design Systems, Inc.CDNS.OQ-5.6%Ciena CorporationCIEN.N-5.4%Palo Alto Networks, Inc.PANW.OQ-5.3%As of 12:00 p.m., the S&P 500.SPXlost 25.96 points, or 0.34%, to 7,660.18 and had posted 7 new 52-week highs and 10 new lows.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nL8N44T1PB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PANG","LU0724618433.USD","HAKY","XTL","SPAM","AIFD","DLTR","CIBR","PSWD","CLOD","CIEN","CDNS","IDNA","FOTO","CDNG","IGV","FTAG","GNOM","BUG","CRWD","CTVA","CIEG","MRNA","XAR","AXUP","MOS","EYES","LGHT","AXON","WDNA","IE00B5949003.HKD","KROP","GUNZ","DG","RSPS","WCLD","WCBR","PBJ","PYZ","VEGI","AIPI","PALU","PANW","MRNX","CRWL","PALD","MRNY","CIEX","CRWC","IHAK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664854756","title":"Vertex Pharmaceuticals Closes Crinetics Pharmaceuticals Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2664854756","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664854756?lang=en_us&edition=fundamental","pubTime":"2026-09-01 21:51","pubTimestamp":1788270662,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals  has completed its acquisition of Crinetics Pharmaceuticals , Vertex said on Tuesday.Following the acquisition's closing, Jonathan Poole will take over Vertex's chief financial officer role, effective Jan. 1, Vertex said. Poole currently serves as Vertex's senior vice president for finance, the company said.Charles Wagner, chief operating and financial officer of Vertex, will expand his COO role to head Crinetics' integration, effective immediately, Vertex said.Price: 549.07, Change: +4.55, Percent Change: +0.83","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0823416689.USD","BK4139","IDNA","LU0234570918.USD","LU2456880835.USD","IE00B4R5TH58.HKD","LU2468319806.SGD","BK4567","IE00BJT1NW94.SGD","LU0079474960.USD","VERX","LU1093756325.SGD","LU2236285917.USD","TBXU","IE00B894F039.SGD","LU0289739699.SGD","LU0417517546.SGD","CRNX","GNMX","LU0320765992.SGD","LU1069344957.HKD","PBE","LU2362541273.HKD","LU1430594728.SGD","IE00B19Z9Z06.USD","LU2089984988.USD","BK4533","IE00B2B36J28.USD","LU0432979614.USD","IE00B19Z3B42.SGD","LU1559883803.SGD","IE00B19Z3581.USD","VRTX","IE00BFTCPJ56.SGD","IE00B19Z9P08.USD","IE0009355771.USD","LU1778281490.HKD","IBBQ","IE00BZ9MQY76.HKD","IE00BJJMRZ35.SGD","LU0058720904.USD","LU0566484027.USD","LU1674673691.USD","LU0889565916.HKD","IBB","BK4532","BBH","IE0002270589.USD","BIB","LU0757428866.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664144854","title":"Vertex Pharmaceuticals completes acquisition of Crinetics Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2664144854","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664144854?lang=en_us&edition=fundamental","pubTime":"2026-09-01 21:25","pubTimestamp":1788269142,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals (VRTX) announced the successful completion of the acquisition of Crinetics Pharmaceuticals (CRNX). Vertex also announced the...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vertex-pharmaceuticals-completes-acquisition-of-crinetics-pharmaceuticals-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vertex-pharmaceuticals-completes-acquisition-of-crinetics-pharmaceuticals-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBBQ","IE00BJT1NW94.SGD","PBE","TBXU","GNMX","LU2362541513.USD","CRNX","VRTX","BK4023","SG9999013999.USD","LU0823416689.USD","IE00B4R5TH58.HKD","SG9999001176.USD","IE00BJJMRZ35.SGD","LU0079474960.USD","IDNA","LU0432979614.USD","LU0320765992.SGD","LU0757428866.USD","IE00B19Z3581.USD","LU0109394709.USD","LU2236285917.USD","LU0061475181.USD","BK4567","IE0002141913.USD","BIB","BBH","IE00B19Z9P08.USD","LU1093756325.SGD","LU1815336091.USD","LU2462157665.USD","LU0889565916.HKD","IE00B2B36J28.USD","VERX","IE00BZ9MQY76.HKD","LU0058720904.USD","LU2237438978.USD","IE00B894F039.SGD","LU1674673428.USD","LU2089984988.USD","SGXZ57979304.SGD","LU1430594728.SGD","IBB","BK4007","LU0417517546.SGD","LU2468319806.SGD","LU1093756168.USD","LU0234570918.USD","LU1035775433.USD","LU0256863811.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664851485","title":"Vertex Names Jonathan Poole CFO Effective Jan. 1, 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2664851485","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664851485?lang=en_us&edition=fundamental","pubTime":"2026-09-01 21:04","pubTimestamp":1788267895,"startTime":"0","endTime":"0","summary":"Vertex names Jonathan Poole CFO effective Jan. 1, 2027Vertex expanded its executive leadership team following the close of its Crinetics acquisition on Sept. 1, 2026.Charles Wagner, EVP and chief oper","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL4Tv8z0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","BK4581","LU2468319806.SGD","LU2462157665.USD","IE00BJT1NW94.SGD","LU0061475181.USD","IE00BZ9MQY76.HKD","LU2362541273.HKD","BK4567","IE00B19Z3B42.SGD","LU0079474960.USD","IBBQ","LU0432979614.USD","LU1093756168.USD","LU1778281490.HKD","IDNA","AMGN","IBB","LU1093756325.SGD","BK4588","LU1057294990.SGD","IE00B19Z9P08.USD","SG9999001176.USD","IE00B19Z9Z06.USD","IE00B2B36J28.USD","LU0109394709.USD","LU1035775433.USD","BK4532","BBH","EVLO","LU0289739699.SGD","IE0009355771.USD","VRTX","PBE","BK4599","BIB","LU2089984988.USD","SG9999013999.USD","SGXZ57979304.SGD","IE00B894F039.SGD","LU0823416689.USD","LU2362540622.SGD","PJP","LU1023059063.AUD","LU0234570918.USD","BK4139","LU1585245621.USD","GNCAQ","TBXU","GNMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664117851","title":"Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team","url":"https://stock-news.laohu8.com/highlight/detail?id=2664117851","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664117851?lang=en_us&edition=fundamental","pubTime":"2026-09-01 21:03","pubTimestamp":1788267780,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nTUA44TDY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0432979614.USD","IE00B19Z9P08.USD","LU1778281490.HKD","IBB","LU0079474960.USD","BK4139","BK4588","LU2417539215.USD","LU2236285917.USD","LU0320765992.SGD","LU1585245621.USD","BK4532","IE00BZ9MQY76.HKD","IE0002270589.USD","LU2468319806.SGD","BK4567","LU1430594728.SGD","IE00B894F039.SGD","IE0002141913.USD","LU2324357040.USD","GNMX","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU0823416689.USD","TBXU","IE00B19Z9Z06.USD","BK4585","LU2237438978.USD","PBE","IE00B2B36J28.USD","LU1674673691.USD","LU1035775433.USD","IE00B19Z3581.USD","BBH","VRTX","LU0234570918.USD","LU0289739699.SGD","IBBQ","LU2456880835.USD","IDNA","SGXZ57979304.SGD","LU0417517546.SGD","SG9999001176.SGD","LU2362541513.USD","LU1674673428.USD","LU2089984988.USD","BIB","IE0009355771.USD","LU1093756168.USD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}]}}